Home・Aktien・Corvus Pharmaceuticals Inc

Corvus Pharmaceuticals Inc

Geschlossen

13.04 -4.4

Buy Sell

Übersicht

Veränderung der Aktienkurses

24h

Aktuell

Min

13.01

Max

13.35

Schlüsselkennzahlen
By Trading Economics
Einkommen	-1.4M -14M
EPS	-0.15
Angestellte	37
EBITDA	312K -12M

Empfehlungen
By TipRanks
Empfehlungen	Starkes Kaufsignal
12-Monats-Prognose	+141.78% upside

Dividenden
By Acuity
Nächstes Ergebnis	6. Aug. 2026

Marktstatistiken
By TradingEconomics
Marktkapitalisierung	-161M 1.2B
Vorheriger Eröffnungskurs	17.44
Vorheriger Schlusskurs	13.04

Corvus Pharmaceuticals Inc Chart

Vergangene Performances sind kein verlässlicher Indikator für zukünftige Ergebnisse.

Ähnliche Nachrichten

24. Juli 2026, 23:56 UTC

Fox Corp shares are lower in after-market hours, with no specific news identified to explain the decline. The stock remains stable within its one-month trading range.

24. Juli 2026, 23:56 UTC

Lumen Technologies Inc shares are higher in after-market trading, continuing fluctuations despite a broader trend of declines over the past month. No specific news identified.

24. Juli 2026, 23:56 UTC

Correlated Moves

State Street Corp shares are lower in after-market trading, reflecting broader market dynamics amid turmoil in the bond markets and sector trends.

24. Juli 2026, 23:56 UTC

Wingstop Inc. shares are higher in after-market trading, recovering from an earlier dip. The stock remains near the lower end of its one-month range.

24. Juli 2026, 23:56 UTC

Cracker Barrel Old Country Store shares are lower in after-market hours. No specific news was identified to explain the decline amid broader market conditions.

24. Juli 2026, 23:56 UTC

Carpenter Technology Corp shares are lower in after-market trading, reflecting broader market trends amid rising concerns in the bond markets.

24. Juli 2026, 23:56 UTC

CMS Energy shares are higher in after-market trading following a slight pullback earlier in the session. The stock has advanced since Friday's close.

24. Juli 2026, 23:56 UTC

DocuSign Inc shares are lower in after-market hours, reflecting a slight decline since Friday's close amid narrow trading fluctuations and no specific news.

24. Juli 2026, 23:56 UTC

JD.Com shares were lower in after-market trading, despite briefly peaking shortly after market open. The stock remains near the upper end of its one-month range.

24. Juli 2026, 23:56 UTC

Correlated Moves

Ares Capital Corp shares declined slightly in after-market trading, reflecting broader financial sector trends amid turmoil in bond markets and rising spreads.

24. Juli 2026, 23:56 UTC

Correlated Moves

ON Semiconductor shares are higher in after-market trading, tracking MACOM's advance. The stock remains near the lower end of its one-month range.

24. Juli 2026, 23:56 UTC

Aptiv PLC shares are trading higher in after-market hours, remaining near the lower end of their one-month trading range. No specific news was identified.

24. Juli 2026, 23:56 UTC

The iShares MSCI South Korea ETF is trading lower in after-market hours, continuing a decline since Friday's close. No specific news was identified.

24. Juli 2026, 23:52 UTC

S&P/Case-Shiller Home Price Index Set to Show 5.2% Increase Amid Mixed Economic Sentiment and Rising Inflation Concerns

24. Juli 2026, 23:52 UTC

South Africa's Upcoming Balance of Trade Data Sparks Caution Amid First Trade Deficit and Global Supply Chain Tensions.

24. Juli 2026, 23:51 UTC

UnitedHealth Group Inc shares are lower in after-market hours, continuing a decline since Friday's close amid broader market trends. No specific news was identified.

24. Juli 2026, 23:51 UTC

Wendy's Co shares are higher in after-market hours, continuing an upward trend from earlier in the session, despite no specific news driving the move.

24. Juli 2026, 23:51 UTC

Pilgrim's Pride Corp shares are higher in after-market trading, continuing gains from Friday's close and nearing the upper end of their one-month trading range.

24. Juli 2026, 23:51 UTC

Axon Enterprise Inc shares are trading lower in after-market hours, reaching a session low amid broader turmoil in bond markets affecting credit investors.

24. Juli 2026, 23:51 UTC

Clear Secure Inc shares are higher in after-market trading, recovering from an initial dip. The stock remains near the lower end of its one-month range.

24. Juli 2026, 23:51 UTC

indie Semiconductor Inc. shares were roughly flat in after-market hours, following four consecutive daily declines amid ongoing market challenges.

24. Juli 2026, 23:51 UTC

Howmet Aerospace Inc shares are higher in after-market trading, continuing a trend of five consecutive sessions of gains. No specific news was identified for the move.

24. Juli 2026, 23:51 UTC

Trimble Inc shares are higher in after-market trading, showing resilience despite challenging macroeconomic conditions and no specific company news identified.

24. Juli 2026, 23:51 UTC

Constellation Brands Inc shares are higher in after-market hours, reflecting modest gains since Friday's close despite broader bond market turmoil.

24. Juli 2026, 23:51 UTC

East West Bancorp Inc shares are higher in after-market trading, reflecting notable strength since Friday's close, with no specific news identified.

24. Juli 2026, 23:51 UTC

U.S. equity indices remain flat as investors weigh mixed earnings, geopolitical tensions, and a surprising drop in jobless claims amidst rising oil prices.

24. Juli 2026, 23:51 UTC

Global equity markets show mixed performance as European indices rise on positive economic data, while Asian markets decline amid geopolitical tensions and rising oil prices.

24. Juli 2026, 23:51 UTC

European equity indices rebound on strong PMI data, while Asian markets decline amid rising oil prices and geopolitical tensions.

24. Juli 2026, 23:51 UTC

Asian equity markets decline amid rising oil prices and geopolitical tensions, while Germany's DAX rises; U.S. stocks remain flat as investors await key economic data.

24. Juli 2026, 23:51 UTC

Axsome Therapeutics Inc shares are lower in after-market hours, reflecting a notable decline since Friday's close, with no specific news identified.

Peer-Vergleich

Kursveränderung

Corvus Pharmaceuticals Inc Prognose

Kursziel

By TipRanks

141.78% Vorteil

12-Monats-Prognose

Durchschnitt 31.6 USD 141.78%

Hoch 40 USD

Tief 27 USD

Basierend auf 5 Wall-Street-Analysten, die in den letzten 3 Monaten 12-Monats-Kursziele für Corvus Pharmaceuticals Inc – Dist angeboten haben.

Rating-Konsens

By TipRanks

Starkes Kaufsignal

5 ratings

Buy

Halten

Sell

Basierend auf 5 Analysten, die in den letzten 3 Monaten Aktienbewertungen für Corvus Pharmaceuticals Inc – Dist abgegeben haben.

Finanzen

Vertriebs- und Verwaltungskosten

Betriebsaufwand

Gewinn vor Steuern

Verkäufe

Umsatzkosten

Bruttogewinn aus dem Verkauf

Zinsaufwand für Schulden

EBITDA

Betriebsergebnis

Über Corvus Pharmaceuticals Inc

Corvus Pharmaceuticals, Inc., a clinical stage biopharmaceutical company, focuses on the development and commercialization of immune modulator product candidates to treat solid cancers, T cell lymphomas, autoimmune, allergic, and infectious diseases. Its lead product candidate is soquelitinib (CPI-818), a selective covalent inhibitor of interleukin 2 inducible T cell kinase (ITK), which is in a multi-center Phase 1/1b clinical trial for the treatment of peripheral T cell lymphoma, solid tumors, and atopic dermatitis. The company is also developing ciforadenant (CPI-444), an oral small molecule antagonist of the A2A receptor that is in Phase 2 clinical trial for the treatment of metastatic renal cell cancer; and mupadolimab (CPI-006), a humanized monoclonal antibody, which is in Phase 1b clinical trial for the treatment of non-small cell lung cancer and head and neck cancer. In addition, it is developing CPI-182, an antibody designed to block inflammation and myeloid suppression that is in investigational new drug application-enabling studies, as well as CPI-935, an adenosine A2B receptor antagonist to prevent fibrosis. Corvus Pharmaceuticals, Inc. has a license afreemnt with Monash University to research, develop, and commercialize certain antibodies directed to CXCR2 for the treatment of human diseases; and Vernalis (R&D) Limited to develop, manufacture, and commercialize products containing certain adenosine receptor antagonists, including ciforadenant, as well as strategic collaboration with Angel Pharmaceuticals Co. Ltd. for the development and commercialization of mupadolimab. Corvus Pharmaceuticals, Inc. was incorporated in 2014 and is based in Burlingame, California.